학술논문
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
Document Type
Article
Author
Gu, Weijie; Han, Weiqing; Luo, Hong; Zhou, Fangjian; He, Dalin; Ma, Lulin; Guo, Hongqian; Liang, Chaozhao; Chong, Tie; Jiang, Jun; Chen, Zhiwen; Wang, Yong; Zou, Qing; Tian, Ye; Xiao, Jun; Huang, Jian; Zhu, Shaoxing; Dong, Qiang; Zhang, Xiaoping; Li, Hanzhong; Yang, Xinfeng; Chen, Chunxia; Li, Junliang; Jin, Chunlei; Zhang, Xiaojing; Ye, Dingwei
Source
In The Lancet Oncology October 2022 23(10):1249-1260
Subject
Language
ISSN
1470-2045